Abstract:BACKGROUND: Circular RNAs can serve as regulators influencing the development of pulmonary hypertension (PH). However, their function in pulmonary vascular intimal injury remains undefined. Thus, we aimed to identify specifically expressed circular RNAs in pulmonary microvascular endothelial cells (PMECs) under hypoxia and PH. METHODS AND RESULTS: Deep RNA sequencing and quantitative real-time polymerase chain reaction revealed that circALMS1 (circular RNA Alstrom syndrome protein 1) was reduced in human PMECs under hypoxia (P<0.0001). Molecular biology and histopathology experiments were used to elucidate the roles of circALMS1 in regulating PMEC dysfunction among patients with PH. The circALMS1 expression was decreased in the plasma of patients with PH (P=0.0315). Patients with lower circALMS1 levels had higher risk of death (P=0.0006). Moreover, the circALMS1 overexpression of adeno-associated viruses improved right ventricular function and reduced pulmonary vascular remodeling in monocrotaline-PH and sugen/hypoxia-PH rats (P<0.05). Furthermore, circALMS1 overexpression promoted apoptosis and inhibited PMEC proliferation and migration under hypoxia by directly downregulating miR-17- 3p (P< 0.05). Dual luciferase assay confirmed the direct binding of circALMS1 to miR-17- 3p and miR-17- 3p binding to its target gene YT521-B homology domain-containing family protein 2 (YTHDF2) (P<0.05). The YTHDF2 levels were also downregulated in hypoxic PMECs (P<0.01). The small interfering RNA YTHDF2 reversed the effects of miR-17- 3p inhibitors on PMEC proliferation, migration, and apoptosis. Finally, the results indicated that, although YTHDF2, as an N(6)-methyladenosine reader protein, contributes to the degradation of many circular RNAs, it could not regulate the circALMS1 levels in PMECs (P=0.9721). CONCLUSIONS: Our study sheds new light on circALMS1-regulated dysfunction of PMECs by the miR-17- 3p/ YTHDF2 pathway under hypoxia and provides insights into the underlying pathogenesis of PH.

Circular RNAs Regulate Vascular Remodelling in Pulmonary Hypertension

Circular RNAs in pulmonary hypertension: Emerging biological concepts and potential mechanism

Characteristics of Circular RNA Expression in Lung Tissues from Mice with Hypoxia‑induced Pulmonary Hypertension.

Circular RNA regulatory role in pathological cardiac remodelling

Non-Coding RNA Networks in Pulmonary Arterial Hypertension

Circular RNAs in Cardiovascular Diseases: Regulation and Therapeutic Applications

Regulation of circular RNAs act as ceRNA in a hypoxic pulmonary hypertension rat model

Circular RNA Sirtuin1 represses pulmonary artery smooth muscle cell proliferation, migration and autophagy to ameliorate pulmonary hypertension via targeting microRNA-145-5p/protein kinase-B3 axis

Circular RNAs as potential biomarkers and therapeutics for cardiovascular disease.

Circular RNAs in Cardiovascular Diseases: Molecular Mechanisms, Therapeutic Advances, and Innovations

Circular RNAs in Cardiovascular Disease: An Overview

The Landscape of Noncoding RNA in Pulmonary Hypertension

Circular RNAs As Potential Theranostics in the Cardiovascular System

Circular RNA: A new expectation for cardiovascular diseases

Circular RNA and cardiovascular diseases

Role of Circular RNAs in the Pathogenesis of Cardiovascular Disease

Circular RNAs: Functions and Clinical Significance in Cardiovascular Disease

Circular RNAs As Novel Regulators, Biomarkers and Potential Therapies in Fibrosis

CircALMS1 Alleviates Pulmonary Microvascular Endothelial Cell Dysfunction in Pulmonary Hypertension.

Circular RNAs in Thoracic Diseases

circRNA CDR1as Promotes Pulmonary Artery Smooth Muscle Cell Calcification by Upregulating CAMK2D and CNN3 via Sponging miR-7-5p